Mutations of the BRCA1 tumor suppressor gene are the most commonly detected alterations in familial breast and ovarian cancer. Although BRCA1 is required for normal mouse development, the molecular basis for its tumor suppressive function remains poorly understood. We show here that BRCA1 increases p53-dependent transcription from the p21 WAF1/CIP1 and bax promoters. We also show that BRCA1 and p53 proteins interact both in vitro and in vivo. The interacting regions map, in vitro, to aa 224 ± 500 of BRCA1 and the C-terminal domain of p53. Tumor-derived transactivation-de®cient BRCA1 mutants are defective in co-activation of p53-dependent transcription and a truncation mutant of BRCA1 that retains the p53-interacting region acts as a dominant inhibitor of p53-dependent transcription. BRCA1 and p53 cooperatively induce apoptosis of cancer cells. The results indicate that BRCA1 and p53 may coordinately regulate gene expression in their role as tumor suppressors.
Introduction
Breast cancer is one of the most common malignancies aecting women. About 5 ± 10% of all cases are estimated to be familial. Susceptibility to early-onset breast and ovarian cancer is conferred by mutations in a gene on chromosome 17q21. This gene, termed BRCA1, has been identi®ed by positional cloning (Miki et al., 1994) . Mutations in the BRCA1 gene account for about 50% of inherited breast cancer cases and 80% of families predisposed to both breast and ovarian cancer.
Much eort has been recently directed at understanding the biochemical function of BRCA1. The human BRCA1 gene encodes an 1863 amino acid nuclear protein that is expressed in a wide variety of adult human tissues (Marquis et al., 1995) . Evidence implicates a role for BRCA1 in the control gene expression. BRCA1 contains a nuclear localization signal (Thakur et al., 1997) , a C-terminal domain that transactivates gene expression when fused to a heterologous DNA binding domain (Chapman and Verma, 1996; Monteiro et al., 1996) and BRCA1 has been found as a component of RNA polymerase II (Scully et al., 1997a) .
Several lines of evidence suggest that BRCA1 protein may play an important role as a suppressor of cell proliferation. Antisense oligonucleotides to BRCA1 mRNA accelerated the growth of normal and malignant mammary epithelial cells (Thompson et al., 1995) . Similarly, NIH3T3 cells with a stable expression of antisense BRCA1 mRNA showed accelerated growth rate, anchorage independent growth, and tumorigenicity in nude mice unlike the parental cell line and stable cell lines expressing sense BRCA1 mRNA (Rao et al., 1996) . In addition, transfection of the wild-type BRCA1 gene inhibited the growth of breast and ovarian cancer cell lines (Holt et al., 1996) . Retroviral introduction of wild-type BRCA1 gene into established MCF7 human breast tumors inhibited the growth of the tumors signi®cantly and also increased the survival of the mice (Holt et al., 1996) . Another evidence that BRCA1 may have an antiproliferative function is that human breast cancers involving mutations in BRCA1 feature increased proliferation, aneuploidy, high S phase fraction and high mitotic grade (Marcus et al., 1997) . Recently we found evidence that exogenous BRCA1 accumulates in the nucleus leading to inhibition of S phase entry possibly through increased transcription of the CDKinhibitor p21, a BRCA1 candidate transcriptional target gene .
A number of observations have also linked BRCA1 to DNA damage response pathways (Brugarolas and Jacks, 1997) . BRCA1 normally colocalizes with Rad51, the human homologue of the Escherichia coli RecA protein, at nuclear dot structures that may be sites of checkpoint processing in S phase cells (Scully et al., 1997c; Tashiro et al., 1996) . Following exposure to DNA damaging agents, BRCA1 becomes hyperphosphorylated and disperses from dot structures and then dynamically accumulates at PCNA-containing replication structures, suggesting a role in the checkpoint response (Scully et al., 1997b) .
The tumor suppressor, p53, is mutated in a wide variety of human cancers and such mutations disrupt the tumor suppressive function of the protein . Several properties of BRCA1 and p53 suggest that these two proteins may functionally interact. Both p53 and BRCA1 are tumor suppressor genes that have been implicated in DNA damage response and repair pathways (Levine, 1997; Scully et al., 1997b; Brugarolas and Jacks, 1997) . Both p53 and BRCA1 are physically-altered by the cellular response to DNA damage, p53 by stabilization and BRCA1 by hyperphosphorylation (Kastan et al., 1991; Scully et al., 1997b) . Both p53 and BRCA1 can activate p21 as a common target gene (El-Deiry et al., 1993; Somasundaram et al., 1997) . In this study we explored the possibility that BRCA1 and p53 may participate in a common pathway of growth regulation. We found that BRCA1 and p53 form stable complexes, both in vitro and in vivo. BRCA1 was found to be a potent coactivator of p53-dependent transcription of the p21 and bax genes. The results suggest that BRCA1 may be a critical cofactor of p53 in its growth inhibitory pathways.
Results

BRCA1 stimulates p53-dependent transcription
Because both p53 and BRCA1 can transactivate the p21 promoter, we investigated the eects of BRCA1 on p53-dependent transcription. BRCA1 either alone or in combination with p53 was cotransfected into SW480 colon carcinoma cells together with a synthetic p53-speci®c reporter (PG13-LUC) (El-Deiry et al., 1993) . The expression of BRCA1 in SW480 (endogenous mutant p53) had no eect on p53-speci®c reporter expression in the absence of exogenous wild-type p53 ( Figure 1a ). As previously reported, transfection of p53 in SW480 cells led to stimulation of the PG13-luciferase reporter (El-Deiry et al., 1993) . Unexpectedly, a dramatic increase in luciferase activity was observed following cotransfection of SW480 cells by BRCA1 and wt p53 expression vectors ( Figure 1a) . We con®rmed the eect of BRCA1 on p53-dependent transcription in MEF p537/7 (Figure 1b) , wild-type p53-expressing HCT116 (Figure 1c) , wild-type p53-expressing MCF7 breast cancer cells (Figure 1d ) and SAOS-2 (p53-null Osteosarcoma) cells (data not shown). The coactivation of p53-dependent transcription by BRCA1 was dose-dependent with respect to BRCA1 and required the presence of wild-type p53 (Figure 1e ).
The transcriptional activity of p53 leads to increased expression of p21 and bax, putative eectors of p53-mediated growth arrest and apoptosis respectively (Levine, 1997). BRCA1 stimulated p53-dependent transcription by 6 ± 8-fold from the p21 and bax promoters, respectively (Figure 1f and g ). As expected, expression of BRCA1 alone activated the p21 promoter . However, BRCA1 did not activate the bax promoter in the absence of exogenous wt p53 (Figure 1g, lane 2) . Because of the increased expression of endogenous p53 target genes in wt p53-expressing cells as compared to cells which lack wt p53 El-Deiry et al., 1994; Blasgosklonny et al., 1997) and because of the lack of availability of BRCA1-null cell lines, it has been dicult to demonstrate that BRCA1 co-activates expression of endogenous p53 targets. It remains unclear whether endogenous p53-dependent p21 expression requires BRCA1. In transfection experiments it is possible to limit the amount of p53, a potent transcription factor, to demonstrate the role of BRCA1 as a coactivator. Because numerous studies have previously correlated the expression of endogenous genes with these reporters, we believe that the coactivation of p53-dependent transcription provides important insight into how BRCA1 may regulate the p53-dependent growth inhibitory pathway. 7/7 or (c) HCT116 cells were cotransfected with dierent combinations (as indicated by a`+') of BRCA1 or its vector, pCR3 (3.5 mg) and p53 or its vector, pCEP4 (2 mg) and PG13-LUC reporter (1 mg). (d) MCF7 cells were transfected by either BRCA1 or its vector, pCR3 (16 mg) and PG13-LUC reporter (4 mg). (e) SW480 cells were transfected with the PG13-LUC reporter (0.5 mg) and increasing concentrations of BRCA1 or its vector, pCR3 (1, 2 and 3.5 mg, respectively) either in the presence or absence of p53 (0.1 mg). (f and g) SW480 cells were cotransfected with dierent combinations (as indicated`+') of BRCA1 or its vector, pCR3 (3.5 mg) and p53 or its vector, pCEP4 (2 mg) along with 1 mg of either the p21-promoter WWP-LUC reporter (f) or the bax-promoter pBAX-LUC reporter (g). Cells were harvested after 24 h of transfection and luciferase activity was measured as described in Materials and methods Slabeled BRCA1 bound to GST-p53 protein but no BRCA1 bound to GST alone (Figure 2a , lanes 5 and 6).
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S-labeled Luciferase protein, a negative control, did not bind to either GST or GST-p53 (Figure 2a,  lanes 3 and 4) . In a similar experiment, COS-7 cell extracts were mixed with beads containing GST or GST-p53 and the bound proteins were analysed by BRCA1 immunoblotting. BRCA1 speci®cally associated with GST-p53 but not GST (Figure 2b ). To investigate the interaction between BRCA1 and p53 proteins in vivo, immunoprecipitations followed by Western blots were performed. In these experiments, an anti-p53 monoclonal antibody directly conjugated to horseradish peroxidase was used to detect p53 directly. Figure  2h ) co-immunoprecipitated with BRCA1. Although p53 protein is well known to be targeted for degradation by HPV-E6 protein in HeLa cells, it was readily detectable in our co-immunoprecipitation assay ( Figure 2f ). Interaction of p53 with CBP has also been demonstrated in HeLa cells . We have consistently observed that endogenous BRCA1 could be speci®cally recovered in association with the exogenous GST-p53 fusion protein linked to agarose beads. We have found no evidence for a BRCA1-dependent supershift of p53-DNA binding site electrophoretic mobility using two dierent anti-human BRCA1 antibodies (data not shown). It is possible that the interaction between BRCA1 and p53 may not be stable enough for gel shift experiments, that BRCA1 is not required for the DNA binding by p53, or that BRCA1 may be present but concealed by other proteins. Although BRCA1 and p53 appear to associate both in vitro and in vivo, we cannot exclude the possibility that the interaction may be indirect.
A novel N-terminal domain of BRCA1 exon 11 interacts with p53 in vitro
To identify the region of BRCA1 that interacts with p53, a series of BRCA1 deletion mutants ( Figure 3c ) translated in vitro in the presence of 35 S-methionine were individually mixed with GST-p53-bound anity resin. The region of BRCA1 extending from aa residues 224 ± 500 was found to be sucient for interaction with p53 ( Figure 3a , lanes 3, 5, 6, 8 and S-methionine-labeled BRCA1, p53 or Luciferase proteins (as indicated above top panel), precipitated with Glutathione-sepharose beads, and analysed by 7.5% SDS ± PAGE (bottom panel). A total of 10% IVT proteins used for binding 9). This region corresponds to the N-terminal region of exon 11 of BRCA1. To further con®rm the minimal BRCA1-interacting region, either GST-BRCA1 fusion protein containing residues 74 ± 500 of BRCA1, was mixed with in vitro synthesized full length p53 protein. p53 protein speci®cally bound to the GST-BRCA1 (Figure 3b , lane 4), whereas Luciferase protein, did not bind to either GST or GST-BRCA1 (Figure 3b, lanes 1  and 2) . This conserved domain has not been noted previously to play a role in BRCA1 function. It is notable that this region is missing from several alternatively spliced forms of BRCA1 (Thakur et al., 1997) .
BRCA1 binds to the C-terminal domain of p53
In order to identify the region of p53 which binds to BRCA1, a series of p53 deletion mutants ( Figure 3f ) were generated as GST-fusion proteins and their ability to interact with in vitro translated full-length BRCA1 or exon 11 of BRCA1 protein was studied. The region of p53 between aa residues 300 ± 393 was found to be sucient for its interaction with BRCA1 ( Figure 3d , lane 4; Figure 3e , lane 4). These results suggest that the physical interaction between p53 and BRCA1 may underlie the BRCA1-dependent stimulation of p53-mediated transcription.
BRCA1 mutants are de®cient in stimulation of p53-dependent transcription
To further explore the biological relevance of the stimulation of p53-dependent transcription by BRCA1, we studied the eect of various synthetic and tumorderived mutant BRCA1 proteins on p53-dependent transcriptional activity. Mutants of BRCA1 lacking the C-terminus transactivation domain or both the Cterminus transactivation domain and the Rad51-interacting domain were poor augmentors of p53-mediated transcriptional activity (Figure 4a) . Similarly, four tumor-derived transactivation-de®cient BRCA1 mutants were defective in stimulation of p53-mediated transcription ( Figure  4a ). These results suggest that an intact transactivation domain within BRCA1 may be required for BRCA1 to increase p53-dependent transcriptional activity.
BRCA1 regulates p21
WAF1/CIP1 through a p53-dependent as well as a p53-independent mechanism p53 had no eect on BRCA1-dependent activation of the p21-promoter in the absence of p53 DNA-binding sites (Figure 4b) , suggesting that the eect of BRCA1 on p53 (Figure 1 ) is speci®c to p53-upregulated genes. Thus it is clear that BRCA1 can activate p21 by a p53-independent pathway that maps to a region distinct from the p53 DNA binding site Somasundaram et al., 1997 and can coactivate p53-dependent gene expression in general only in the presence of p53 binding sites (Figures 1 and 4) . Dominant negative inhibition of p53-dependent transcriptional activity by a BRCA1 truncation mutant retaining the p53-interacting domain
The BRCA1 mutant D500 ± 1863 , which lacks both the Rad51-interacting and C-terminal transactivation domains, was used to test the hypothesis that truncating BRCA1 mutants retaining the newly-identi®ed p53-interacting domain may act as dominant negative inhibitors of p53-mediated transcription. We hypothesized that this truncated BRCA1 protein might inhibit p53-mediated transcriptional activity by competing with endogenous BRCA1 for p53. Co-transfection of truncated BRCA1 (D500 ± 1863) with p53 inhibited p53-mediated transcription in a dose-dependent manner (Figure 4c ). The apparent dominant negative inhibition of p53 was overcome by increasing amounts of exogenous wt BRCA1 (Figure 4d ). We speculate that the truncated BRCA1 protein, which does not have a nuclear localization signal, may associate with p53 prior to its entry into the nucleus.
Cooperation between BRCA1 and p53 in apoptosis induction p53-mediated apoptosis plays a major role in tumor suppression. One mechanism by which p53 mediates apoptosis is by its ability to activate transcription (Haupt et al., 1995; Chen et al., 1996) . In order to determine if BRCA1 has any eect on p53-mediated apoptosis through its ability to stimulate p53-mediated transcription, p53 was co-transfected with either BRCA1 into SW480 cells. Apoptotic cells were identi®ed by TUNEL assay and the apoptotic cells (%) was quanti®ed at 40 h following transfection (Table 1) . Vector-alone transfected cells showed a low level of apoptosis. Transfection of p53 or BRCA1 alone induced apoptosis up to tenfold and cotransfection of BRCA1 with p53 increased further the apoptotic cells (Table 1 ) suggesting p53 and BRCA1 may cooperate to induce apoptosis. SW480 cells express low levels of endogenous BRCA1 (Somasundaram et al., 1997), and so it is possible that the assay was loaded directly onto the gels to document input proteins (top panel). (b) GST ± BRCA1 (aa 74 ± 500) was mixed with IVT 35 S-methionine-labeled p53 (lanes 3 and 4) or Luciferase (lanes 1 and 2) and the bound proteins were analysed as in panel a. (c) Schematic diagram identifying the p53-binding region of human BRCA1. The structure of BRCA1 protein is shown, including the nuclear localization signal (NLS; purple), the transactivation domain (TA; green), the RING-®nger domain (dark blue), the Rad51-interacting domain (red) and the p53 binding domain (yellow). Mutants of BRCA1 tested for interaction with p53 are shown along with their ability to interact with p53 protein in vitro (`+' indicates interaction while`7' indicates no interaction). (d) GST, GSTp53, GST-p53 (aa 1 ± 200), or GST-p53 (aa 201 ± 393) fusion proteins were mixed with IVT 35 S-methionine-labeled BRCA1 and analysed as in panel a. (e) GST, GST-p53, GST-p53 (aa 1 ± 43), GST-p53 (aa 100 ± 300) and GST-p53 (aa 300 ± 393) proteins were mixed with IVT 35 S-methionine-labeled BRCA1 exon 11 protein and analysed as in panel a. (f) Schematic diagram of human p53 identifying the BRCA1-interacting domain. The structure of the p53 protein is shown including the transactivation domain (TA; blue), the DNA-binding domain (red), the tetramerization domain (TD; green) and the BRCA1-binding domain (bracket). Truncation mutants of p53 are shown along with their ability to interact with BRCA1 in vitro (right;`+' indicates interaction whilè 7' indicates no interaction) BRCA1 regulates of p53 function H Zhang et al observed levels of apoptosis following p53 transfection alone may already involve cooperation with BRCA1. The modest increase in apoptosis due to exogenous BRCA1 should also be considered in the context that the upper limit for (%) apoptosis (range of 20 ± 50%) in these experiments is the transfection eciency. The results suggest a scenario wherein BRCA1 may enhance the induction of apoptosis by p53 possibly through stimulation of p53's transcriptional activity.
Discussion
Both p53 and BRCA1 are physically-altered by the cellular response to DNA damage, p53 by stabilization and BRCA1 by hyperphosphorylation (Kastan et al., 1991; Scully et al., 1997b) . Both proteins can activate expression of the cell cycle inhibitor p21 (El-Deiry et al., 1993; Somasundaram et al., 1997) . Because both BRCA1 and p53 are implicated in regulation of gene transcription, control of cell growth and response to DNA damage, we sought to investigate the possibility of a functional cross-talk between these two proteins. The results suggest that BRCA1 and p53 can physically associate, both in vitro and in vivo and function in a common pathway of tumor suppression. The ability of BRCA1 to biochemically modulate p53 function suggests that this may be a fundamental role of BRCA1 in tumor suppression. It is noteworthy that inherited defects of either p53 or BRCA1 can lead to the development of breast cancer in humans (Malkin et al., 1990; Miki et al., 1994) .
Our results reveal that BRCA1 is a potent activator of p53-dependent transcription by demonstrating that BRCA1 potentiates p53-activated transcription of the 
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H Zhang et al p21 and the bax promoters. The role of p53 as a transcription factor is well-established (Vogelstein and Kinzler, 1992 ) and appears to be important for its ability to arrest cell cycle progression as well as to induce apoptosis (Levine, 1997). BRCA1 has been postulated to function as a coactivator of transcription, based on its localization as a component of RNA polymerase II holoenzyme and transactivation function (Chapman and Verma, 1996; Monteiro et al., 1996; Somasundaram et al., 1997; Scully et al., 1997a) . The observation that BRCA1 is a transcriptional coactivator of p53, including strong upregulation of expression of the bax gene, provides a novel mechanism for apoptosis induction and tumor suppression by BRCA1. BRCA1 serves a co-stimulatory role in p53-mediated transcription from p21, suggesting BRCA1 is involved in both p53-dependent transcription and independent transcription. This ®nding is consistent with previous data demonstrating that p21 can be activated by other p53 independent pathways (El-Deiry et al., 1998). During gene expression, a complex of activators, coactivators, and basal factors are necessary to stabilize the interactants and provide transcriptional speci®city. BRCA1 may link a variety of dierent DNA binding factors such as p53 to the components of the basal transcription machinery. Here we show that p53 and BRCA1 form a speci®c protein complex in vitro and in vivo. An N-terminal segment of BRCA1 exon 11 extending from residues 224 ± 500 is sucient for its interaction with p53. Interestingly, exon 11 is deleted in several naturally occurring isoforms of BRCA1 (Thakur et al., 1997) , leading to speculation that the inability of the BRCA1Dexon11 mutant to bind to p53 may be a regulatory mechanism for BRCA1. Our ®ndings also suggest that BRCA1 binding to p53 may not be mediated by RAD51, RNA polymerase II holoenzyme or BARD1 since they bind to dierent regions on BRCA1 (Scully et al., 1997a,c; Wu et al., 1996) . Post-translational modifications of the C-terminus of p53 have been shown to play an important role in controlling p53-speci®c DNA binding (Levine, 1997) . Phosphorylation, acetylation, antibody binding, or deletion of this region can convert p53 from an inert to an active form for DNA binding . Therefore allosteric regulation of p53 by distinct cellular signaling pathways modulates the conversion between latent and activated forms of p53. Our results show BRCA1 binds to the C-terminus of p53. BRCA1 may activate p53 by altering the conformation of p53 through direct physical binding and/or modi®cation of the C-terminal p53. In addition, p53 may be bridged to the basal transcriptional machinery by BRCA1.
Mutation in the C-terminus of BRCA1, which contains its transactivation domain (Chapman and Verma, 1996; Monteiro et al., 1996) , occurs in hereditary breast cancer (Couch and Weber, 1994) . Such mutants of BRCA1 are defective in the ability to activate p21 WAF1/CIP1 . Our study indicates that the tumor-derived BRCA1 mutants carrying point mutations in the C-terminus are also defective in stimulation of p53-dependent transcription. Because BRCA1 interaction with p53 maps to the Nterminal region of BRCA1 we hypothesized that truncated-BRCA1 proteins, the most common forms found in hereditary breast and ovarian cancer, may compete for sites on p53 and perhaps inhibit p53 function. We found that truncated BRCA1 is a potent dominant negative inhibitor of p53-dependent transcription, and that this could be reversed by excess wild-type BRCA1. These results would predict a defective p53 transcriptional activity in certain cancer cells, a hypothesis which can be tested in the future through the isolation of breast and ovarian cancer cell lines that express truncated BRCA1 proteins.
Although p53 and BRCA1 appear to physically interact directly in vitro, we found no evidence for stimulation of BRCA1-dependent transactivation of p21 by exogenous p53 in the absence of p53-DNA binding sites. BRCA1 could, however, greatly stimulate p53-dependent activation of the bax promoter, in the absence of p53-independent activation of this promoter by BRCA1. These observations argue that, in vivo, certain DNA regulatory elements serve to recruit p53 to certain genes. In such situations the presence of p53 protein favors the chance for local association with BRCA1 and cooperative activation is observed. In our system using either the p21 or bax promoter, the combination of p53 and BRCA1 leads to more than an additive increase in gene expression, but it is not clear whether BRCA1 is required for p53-dependent transcription, because of the lack of availability of BRCA1-null cell lines. The BRCA1-knockout embryos appear to express p21 (Hakem et al., 1996) and the current model is that this may be due to genomic instability and subsequent p53 activation (Brugarolas and Jacks, 1997) . The dominant negative action of truncated BRCA1 on p53-dependent transcription hints at the possibility that BRCA1 may be required for p53-dependent transcription. Our results argue that in somatic cells, BRCA1 can activate p53 function leading to tumor suppression. Future experiments will need to speci®cally investigate the tissue speci®city of these responses as well as why BRCA1 inactivation leads primarily to breast and ovarian cancer.
The induction of apoptosis by p53 is critical for its tumor suppressor function (Symonds et al., 1994) . The results presented in Table 1 suggest that BRCA1 cooperates with p53 in inducing apoptosis. Altogether, our data suggest that BRCA1 acts as a coactivator of p53-driven gene expression and may play an important role in cell growth arrest apoptosis, and/or DNA damage repair processes. It is not known at this time if BRCA1 is required for transcriptiondependent p53 action. The possibility that the complex of BRCA1 and p53 may directly participate in DNA damage recognition and/or repair could not be excluded. In summary, we have identi®ed a physical and functional association between the tumor suppressors p53 and BRCA1, linking their biochemical eects to a common pathway of tumor suppression.
Materials and methods
Cell lines and culture conditions
The SW480 human colon adenocarcinoma cell line was maintained in culture as previously described . HCT116 human colon cancer cells (wt p53) were provided by Bert Volgestein (Johns Hopkins University), and cultured as previously described (McDonald et al., 1996) . Mouse embryo ®broblasts (p53 7/7 ) were provided by Tyler Jacks (Massachusetts Institute of Technology). SAOS-2, HeLa, COS7, HBL100, U2OS and 293 cells were obtained from ATCC.
Reporters and expression plasmids
The pWWP-LUC, PG13-LUC and pCEP4-p53 plasmids were provided by B Vogelstein (Johns Hopkins University). pBAX-LUC was obtained from Karen Vousden (NCI, Frederick, MD). The 7143 p21 Luc reporter was described previously . pGEX-5X1 was purchased from Pharmacia, and the pCR3 and pCR3.1 were purchased from Invitrogen. The Luciferase T7 control DNA was obtained from Promega. Wild-type and mutant BRCA1 (Dexon11, D500 ± 1863, D1312 ± 1863, P1749R, Y1853insA and Q1756insC) were described previously (Thakur et al., 1997; Somasundaram et al., 1997) . The p53 cDNA was ampli®ed using the primers 5'-AAGCTTGCCACCATGGAGGAGCCGCAGTCA-3' and 5'-ATGCGGCCGCTCAGTCTGAGTCAG-3' and the human p53 cDNA as template. The resulting PCR product was sub-cloned into pCR3.1 Using the human BRCA1 cDNA as template, various BRCA1 fragments were ampli®ed and cloned into pCR3.1 for in vitro translation. The primers used were: For BRCA1 exon 11 (224 ± 1365): 5'-TAAGCTTGCCACCATGGCTGCTTGTGAA-TT-3' and 5'-ACTCGAGTCATAAGTTTGAATCCAT-3'; BRCA1 (1 ± 1056) 5'-GCAAGCTTGCCACCATGGATT-TATCTGCTCTTCGC-3' and 5'-GGAGCCCACTTCAT-TAGTAC-3'; BRCA1(1 ± 98) 5'-GCAAGCTTGCCACCA-TGGATTTATCTGCTCTTCGC-3' and 5'-ACCTGTGTC-AAGCTGAAAAGCAC-3'; BRCA1 (91 ± 500) 5'-AAG-CTTGCCACCATGTGTGCTTTTCAGCTT-3' and 5'-TC-TCGAGTCAATTTGTGAGGGGACG-3'; BRCA1 (224 ± 500) 5'-TAAGCTTGCCACCATGGCTGCTTGTGAATT-T-3' and 5'-TCTCGAGTCAATTTGTGAGGGGACG-3'. For production of GST-p53 fusion proteins, full-length and dierent fragments of p53 were ampli®ed using the following primers: wt p53 5'-GTCGAATTCGAGGAG-CCGCAGTCAGAT-3' and 5'-ATGCGGCCGCTCAGTC-TGAGTCAG-3'; p53 (1 ± 43) 5'-GTCGAATTCGAGGA-GCCGCAGTCAGAT-3' and 5'-ATGCGGCCGCCAAAT-CATCCATTGC-3'; p53 (1 ± 200) 5'-GTCGAATTCGAG-GAGCCGCAGTCAGAT-3' and 5'-TACTCGAGATTTC-CTTCCACTCGGAT-3'; p53 (100 ± 300) 5'-ATGAATTC-CAGAAAACCTACCAG-3' and 5'-TACTCGAGGGCA-GCTCGTGGTG-3'; p53 (201 ± 393) 5'-ATGAATTCT-TGCGTGTGGAGTATTTG-3' and 5'-ATGCGGCCGCT-CAG-TCTGAGTCAG-3'; p53 (300 ± 393) 5'-ATGAAT-TCCCCCCAGGGAGCACT-3' and 5'-TGCGGCCGCT-CAGTCTG-AGTCAG-3'. The PCR products were cloned into the following restriction sites of the pGEX-5X1 GST vector: wt p53 EcoRI/NotI; p53 (1 ± 43) EcoRI/NotI; p53 (1 ± 200) EcoRI/XhoI; p53 (100 ± 300) EcoRI/XhoI; p53 (201 ± 393) EcoRI/NotI; p53 (300 ± 393) EcoRI/NotI. To make the GST ± BRCA1 (91 ± 500) fusion protein, the BRCA1 (91 ± 500) product was generated by PCR from the human BRCA1 cDNA with primers 5'-AGAA-TTCTGTGCTTTTCAGCTT-3' and 5'-TCTCGAGTCAA-TTTGTGAGGGGACG-3'. After digestion with EcoRI and XhoI, the fragment was subcloned into pGEX-5X1. The cloned DNA sequence of all of the above vectors was veri®ed.
Transfections and luciferase assays SW480 and MEF cells were transfected using lipofectin and lipofectamine (GIBCO) respectively as described previously (El-Deiry et al., 1993) . SAOS2 cells were transfected using the calcium phosphate-precipitation method (Somasundaram et al., 1996) . Luciferase assays were performed as described .
GST-fusion protein puri®cation
Various pGEX-5X1 fusion constructs were transformed into DH5a E. coli (GIBCO/BRL). The GST-p53 or GST ± BRCA1 (91 ± 500) proteins were produced following incubation of the bacteria with 0.1 ± 1 mM IPTG at 308C for 2 ± 3 h. The cell pellet was resuspended in PBS and sonicated. The soluble GST-fusion proteins were immobilized onto Glutathione Sepharose 1 4B beads (Pharmacia).
In vitro interaction between BRCA1 and p53
In vitro translations were carried out in the presence of 40 mCi [
35 S]methionine (NEN) using TNT 1 coupled reticulocyte lysate system (Promega). For in vitro binding assays, 5 ± 20 ml of in vitro translated 35 S-labeled proteins or cell lysate from 1610 7 cells was incubated with glutathione-sepharose beads containing GST-fusion proteins from 10 ml bacterial cultures. After washing, the bound proteins were eluted with 30 ml SDS sample buer and resolved by 7.5% SDS ± PAGE followed by fluorography. In experiments where unlabeled cell extracts were used, after SDS ± PAGE separation, the proteins were transferred to Hybond TM P membrane (Amersham). Immunoblotting was carried out using anti-BRCA1 monoclonal antibody (SG11, 1 : 100 dilution; Oncogene Science) and ECL TM (Amersham).
TUNEL assay
SW480 cells (3610 4 /well) were transfected with mammalian expression vectors (1 mg) in 8-well chamber slides. The cells were ®xed with neutral buered formalin after 40 h and analysed for¯uorescence emission by TUNEL assay using the Apoptag Plus In Situ apoptosis detection kitFluorescine (ONCOR) as previously described . Brie¯y, ®xed cells were incubated with digoxigeninlabeled nucleotides and TdT enzyme followed by washing with PBS and incubation with an anti-digoxigenin-FITC conjugate. In each experiment, the % of TdT(+) cells was determined by counting at least 300 cells from 5 ± 10 random transfected ®elds.
Immunoprecipitations and immunoblotting of BRCA1 and p53
Immunoprecipitation was carried out using an immunoprecipitation kit (Boehringer Mannheim). About 1610 7 cells were lysed in Wash Buer 1 (50 mM Tris, pH 7.5, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate plus protease inhibitor cocktail). After preclearing with protein G-sepharose beads, lysates were mixed with antibodies (1 mg/ml) and protein G-agarose. The antibodies used are anti-BRCA1, (C20; Santa Cruz) and (SG11; Oncogene Science), anti-p16 (Ab1; Oncogene Science), anti-MDM-2 (Ab1; Oncogene Science) and anti-p53 (Ab-6; Oncogene Science). The beads were washed three times with Wash Buer I, one time with Wash Buer 2 (50 mM Tris, pH 7.5, 500 mM NaCl. 0.1% NP40, 0.05% sodium deoxycholate) and one time with Wash Buer 3 (50 mM Tris, pH 7.5, 0.1% NP40, 0.05% sodium deoxycholate). Samples were solubilized in SDSsample buer by boiling for 5 min and separated by 7.5% SDS ± PAGE. After transferring, the membranes were incubated with anti-p53 antibody conjugated to HRP (1 : 200 dilution of p53DO1; Santa Cruz) or anti-BRCA1 antibody (1 : 200 dilution of SG11; Oncogene Science). A 1 : 300 dilution of anti-mouse HRP (Amersham) was used to detect BRCA1.
